- Polythiophene-Encapsulated Bimetallic Au-Fe3O4 Nano-Hybrid Materials: A Potential Tandem Photocatalytic System for Nondirected C(sp2)-H Activation for the Synthesis of Quinoline Carboxylates
-
Hetero-oligophenylene derivative 3 appended with thiophene moieties has been designed and synthesized which undergoes aggregation to form J-type fluorescent aggregates in in H2O/THF (7/3) media. These aggregates served as reactors for the preparation of bimetallic Au-Fe3O4 NPs. During the reduction process, aggregates of derivative 3 were oxidized to the polythiophene species 4. Interestingly, the polythiophene species 4, having a fibrous morphology, served as a shape- and morphology-directed template for assembly of bimetallic Au-Fe3O4 NPs in a flower-like arrangement. Furthermore, polythiophene-encapsulated bimetallic 4:Au-Fe3O4 nanohybrid materials served as an efficient and recyclable catalytic system for C(sp2)-H bond activation of unprotected electron-rich anilines for the construction of synthetically versatile quinoline carboxylates via C-H activation, carbonylation, and subsequent annulation under mild and eco-friendly conditions (aqueous media, room temperature, visible-light irradiation, and aerial conditions).
- Kaur, Mandeep,Pramanik, Subhamay,Kumar, Manoj,Bhalla, Vandana
-
p. 2007 - 2021
(2017/08/17)
-
- SUBSTITUTED THIAZOLE COMPOUNDS
-
The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.
- -
-
Page/Page column 46-47
(2014/06/24)
-
- NEW CHEMICAL COMPOUNDS
-
The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
- -
-
Page/Page column 57
(2012/04/23)
-
- SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
-
This invention provides compounds of formula (I): wherein R1a, R1, R2a, and R2b have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
- -
-
Page/Page column 60
(2011/12/04)
-
- HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS
-
The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
- -
-
Page/Page column 90
(2011/11/06)
-
- From fragment screening to in vivo efficacy: Optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (bace1)
-
Using fragment-based screening of a focused fragment library, 2-aminoquinoline 1 was identified as an initial hit for BACE1. Further SAR development was supported by X-ray structures of BACE1 cocrystallized with various ligands and molecular modeling studies to expedite the discovery of potent compounds. These strategies enabled us to integrate the C-3 side chain on 2-aminoquinoline 1 extending deep into the P2′ binding pocket of BACE1 and enhancing the ligand's potency. We were able to improve the BACE1 potency to subnanomolar range, over 106-fold more potent than the initial hit (900 μM). Further elaboration of the physical properties of the lead compounds to those more consistent with good blood-brain barrier permeability led to inhibitors with greatly improved cellular activity and permeability. Compound 59 showed an IC50 value of 11 nM on BACE1 and cellular activity of 80 nM. This compound was advanced into rat pharmacokinetic and pharmacodynamic studies and demonstrated significant reduction of Aβ levels in cerebrospinal fluid (CSF).
- Cheng, Yuan,Judd, Ted C.,Bartberger, Michael D.,Brown, James,Chen, Kui,Fremeau Jr., Robert T.,Hickman, Dean,Hitchcock, Stephen A.,Jordan, Brad,Li, Vivian,Lopez, Patricia,Louie, Steven W.,Luo, Yi,Michelsen, Klaus,Nixey, Thomas,Powers, Timothy S.,Rattan, Claire,Sickmier, E. Allen,St. Jean Jr., David J.,Wahl, Robert C.,Wen, Paul H.,Wood, Stephen
-
p. 5836 - 5857
(2011/10/09)
-